Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
Xiaoning Wang,1 Amit Roy,2 Andreas Hochhaus,3 Hagop M Kantarjian,4 Tai-Tsang Chen,5 Neil P Shah6 1Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Lawrenceville, NJ, USA; 2Clinical Pharmacology and Pharmacometrics, Research and Development, Bristol-Myers Squibb, Lawrenceville, NJ,...
Saved in:
Main Authors: | Wang X (Author), Roy A (Author), Hochhaus A (Author), Kantarjian HM (Author), Chen TT (Author), Shah NP (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetics of Dasatinib in Healthy Subjects
by: Walaa B. Hassouneh, et al.
Published: (2024) -
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions
by: Christina Kovar, et al.
Published: (2024) -
Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
by: Phirangkul Kerdpanich, et al.
Published: (2018) -
Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009) -
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
by: Lisa van derHeijden, et al.
Published: (2023)